View Item 

Show simple item record

Raf kinase inhibitor protein (RKIP) deficiency decreases latency of tumorigenesis and increases metastasis in a murine genetic model of prostate cancer

dc.contributor.authorEscara‐wilke, Juneen_US
dc.contributor.authorKeller, Jill M.en_US
dc.contributor.authorIgnatoski, Kathleen M. Woodsen_US
dc.contributor.authorDai, Jinluen_US
dc.contributor.authorShelley, Gregoryen_US
dc.contributor.authorMizokami, Atsushien_US
dc.contributor.authorZhang, Jianen_US
dc.contributor.authorYeung, Miranda Len_US
dc.contributor.authorYeung, Kam C.en_US
dc.contributor.authorKeller, Evan T.en_US
dc.date.accessioned2015-02-19T15:40:24Z
dc.date.available2016-04-01T15:21:07Zen
dc.date.issued2015-02en_US
dc.identifier.citationEscara‐wilke, June ; Keller, Jill M.; Ignatoski, Kathleen M. Woods; Dai, Jinlu; Shelley, Gregory; Mizokami, Atsushi; Zhang, Jian; Yeung, Miranda L; Yeung, Kam C.; Keller, Evan T. (2015). "Raf kinase inhibitor protein (RKIP) deficiency decreases latency of tumorigenesis and increases metastasis in a murine genetic model of prostate cancer." The Prostate 75(3): 292-302.en_US
dc.identifier.issn0270-4137en_US
dc.identifier.issn1097-0045en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/110558
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherLNCaPen_US
dc.subject.otherTRAMP modelen_US
dc.subject.othermetastasis suppressor geneen_US
dc.titleRaf kinase inhibitor protein (RKIP) deficiency decreases latency of tumorigenesis and increases metastasis in a murine genetic model of prostate canceren_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/110558/1/pros22915.pdf
dc.identifier.doi10.1002/pros.22915en_US
dc.identifier.sourceThe Prostateen_US
dc.identifier.citedreferenceBerman‐Booty LD, Sargeant AM, Rosol TJ, Rengel RC, Clinton SK, Chen CS, Kulp SK. A review of the existing grading schemes and a proposal for a modified grading scheme for prostatic lesions in TRAMP mice. Toxicol Pathol 2012; 40 ( 1 ): 5 – 17.en_US
dc.identifier.citedreferenceGeorge AJ, Holsinger RM, McLean CA, Tan SS, Scott HS, Cardamone T, Cappai R, Masters CL, Li QX. Decreased phosphatidylethanolamine binding protein expression correlates with Abeta accumulation in the Tg2576 mouse model of Alzheimer's disease. Neurobiol Aging 2006; 27 ( 4 ): 614 – 623.en_US
dc.identifier.citedreferenceEscara‐Wilke J, Yeung K, Keller ET. Raf kinase inhibitor protein (RKIP) in cancer. Cancer Metastasis Rev 2012; 31 ( 3–4 ): 615 – 620.en_US
dc.identifier.citedreferenceChatterjee D, Bai Y, Wang Z, Beach S, Mott S, Roy R, Braastad C, Sun Y, Mukhopadhyay A, Aggarwal BB, Darnowski J, Pantazis P, Wyche J, Fu Z, Kitagwa Y, Keller ET, Sedivy JM, Yeung KC. RKIP sensitizes prostate and breast cancer cells to drug‐induced apoptosis. J Biol Chem 2004; 279 ( 17 ): 17515 – 17523.en_US
dc.identifier.citedreferenceOdabaei G, Chatterjee D, Jazirehi AR, Goodglick L, Yeung K, Bonavida B. Raf‐1 kinase inhibitor protein: Structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res 2004; 91: 169 – 200.en_US
dc.identifier.citedreferenceBonavida B, Jazirehi A, Vega MI, Huerta‐Yepez S, Baritaki S. Roles each of Snail, Yin Yang 1 and RKIP in the regulation of tumor cells chemo‐immuno‐resistance to apoptosis. For Immunopathol Dis Therap 2013; 4 ( 1 ): 79 – 92.en_US
dc.identifier.citedreferenceFu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, Yao Z, Keller ET. Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst 2003; 95 ( 12 ): 878 – 889.en_US
dc.identifier.citedreferenceTheroux S, Pereira M, Casten KS, Burwell RD, Yeung KC, Sedivy JM, Klysik J. Raf kinase inhibitory protein knockout mice: Expression in the brain and olfaction deficit. Brain Res Bull 2007; 71 ( 6 ): 559 – 567.en_US
dc.identifier.citedreferenceThalmann GNN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S, Chung LW. LNCaP progression model of human prostate cancer: Androgen‐independence and osseous metastasis. Prostate 2000; 44 ( 2 ): 91 – 103; Jul 101;144(102).en_US
dc.identifier.citedreferenceFu Z, Kitagawa Y, Shen R, Shah R, Mehra R, Rhodes D, Keller PJ, Mizokami A, Dunn R, Chinnaiyan AM, Yao Z, Keller ET. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate 2006; 66 ( 3 ): 248 – 256.en_US
dc.identifier.citedreferenceBohl CR, Harihar S, Denning WL, Sharma R, Welch DR. Metastasis suppressors in breast cancers: Mechanistic insights and clinical potential. J Mol Med (Berl) 2014; 92 ( 1 ): 13 – 30.en_US
dc.identifier.citedreferenceShoushtari AN, Szmulewitz RZ, Rinker‐Schaeffer CW. Metastasis‐suppressor genes in clinical practice: Lost in translation ? Nat Rev Clin Oncol 2011; 8 ( 6 ): 333 – 342.en_US
dc.identifier.citedreferenceDangi‐Garimella S, Yun J, Eves EM, Newman M, Erkeland SJ, Hammond SM, Minn AJ, Rosner MR. Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let‐7. EMBO J 2009; 28 ( 4 ): 347 – 358.en_US
dc.identifier.citedreferenceGreenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995; 92 ( 8 ): 3439 – 3443.en_US
dc.identifier.citedreferenceKaplan‐Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, Maddison LA, Foster BA, Greenberg NM. Pathobiology of autochthonous prostate cancer in a pre‐clinical transgenic mouse model. Prostate 2003; 55 ( 3 ): 219 – 237.en_US
dc.identifier.citedreferenceIttmann M, Huang J, Radaelli E, Martin P, Signoretti S, Sullivan R, Simons BW, Ward JM, Robinson BD, Chu GC, Loda M, Thomas G, Borowsky A, Cardiff RD. Animal models of human prostate cancer: The consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res 2013; 73 ( 9 ): 2718 – 2736.en_US
dc.identifier.citedreferenceMarcus DM, Goodman M, Jani AB, Osunkoya AO, Rossi PJ. A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008. Prostate Cancer Prostatic Dis 2012; 15 ( 3 ): 283 – 288.en_US
dc.identifier.citedreferenceKeller ET. Metastasis suppressor genes: A role for raf kinase inhibitor protein (RKIP). Anticancer Drugs 2004; 15 ( 7 ): 663 – 669.en_US
dc.identifier.citedreferenceLi HZ, Gao Y, Zhao XL, Liu YX, Sun BC, Yang J, Yao Z. Effects of raf kinase inhibitor protein expression on metastasis and progression of human breast cancer. Mol Cancer Res 2009; 7 ( 6 ): 832 – 840.en_US
dc.identifier.citedreferenceLi HZ, Wang Y, Gao Y, Shao J, Zhao XL, Deng WM, Liu YX, Yang J, Yao Z. Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer. Mol Cancer Res 2008; 6 ( 6 ): 917 – 928.en_US
dc.identifier.citedreferenceCao J, Yan Q. Histone demethylases set the stage for cancer metastasis. Sci Signal 2013; 6 ( 273 ): pe15, 11–12.en_US
dc.identifier.citedreferenceValastyan S, Weinberg RA. Tumor metastasis: Molecular insights and evolving paradigms. Cell 2011; 147 ( 2 ): 275 – 292.en_US
dc.identifier.citedreferenceWu K, Bonavida B. The activated NF‐kappaB‐Snail‐RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs. Crit Rev Immunol 2009; 29 ( 3 ): 241 – 254.en_US
dc.identifier.citedreferenceUzgare AR, Kaplan PJ, Greenberg NM. Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer. Prostate 2003; 55 ( 2 ): 128 – 139.en_US
dc.identifier.citedreferenceAl‐Mulla F, Bitar MS, Taqi Z, Yeung KC, RKIP: Much more than Raf kinase inhibitory protein. J Cell Physiol 2013; 228 ( 8 ): 1688 – 1702.en_US
dc.identifier.citedreferenceYeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, Fee F, Katsanakis KD, Rose DW, Mischak H, Sedivy JM, Kolch W. Suppression of Raf‐1 kinase activity and MAP kinase signalling by RKIP. Nature 1999; 401 ( 6749 ): 173 – 177.en_US
dc.identifier.citedreferenceYousuf S, Duan M, Moen EL, Cross‐Knorr S, Brilliant K, Bonavida B, LaValle T, Yeung KC, Al‐Mulla F, Chin E, Chatterjee D. Raf kinase inhibitor protein (RKIP) blocks signal transducer and activator of transcription 3 (STAT3) activation in breast and prostate cancer. PLoS ONE 2014; 9 ( 3 ): e92478.en_US
dc.identifier.citedreferenceChatterjee D, Sabo E, Tavares R, Resnick MB. Inverse association between Raf Kinase Inhibitory Protein and signal transducers and activators of transcription 3 expression in gastric adenocarcinoma patients: Implications for clinical outcome. Clin Cancer Res 2008; 14 ( 10 ): 2994 – 3001.en_US
dc.identifier.citedreferenceBeshir AB, Ren G, Magpusao AN, Barone LM, Yeung KC, Fenteany G. Raf kinase inhibitor protein suppresses nuclear factor‐kappaB‐dependent cancer cell invasion through negative regulation of matrix metalloproteinase expression. Cancer Lett 2010; 299 ( 2 ): 137 – 149.en_US
dc.identifier.citedreferenceKlysik J, Theroux SJ, Sedivy JM, Moffit JS, Boekelheide K. Signaling crossroads: The function of Raf kinase inhibitory protein in cancer, the central nervous system and reproduction. Cell Signal 2008; 20 ( 1 ): 1 – 9.en_US
dc.identifier.citedreferenceZeng L, Imamoto A, Rosner MR. Raf kinase inhibitory protein (RKIP): A physiological regulator and future therapeutic target. Expert Opin Ther Targets 2008; 12 ( 10 ): 1275 – 1287.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
pros22915.pdf
Size:
1.520MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.